You are here

vaccines

Pfizer takes Poland to court over alleged missed COVID-19 vaccine payments

Pfizer takes Poland to court over alleged missed COVID-19 vaccine payments

Fierce Pharma

Flag link:

WHO authorizes emergency use of Novavax's updated COVID shot

WHO authorizes emergency use of Novavax's updated COVID shot

Reuters

Flag link:

Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators

Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators

Fierce Pharma

clinical trials

pneumococcal disease

Flag link:

European Patent Office declares Moderna mRNA patent invalid

European Patent Office declares Moderna mRNA patent invalid

Reuters

Moderna Therapeutics

Flag link:

Is Novavax, the latecomer COVID vaccine, worth the wait?

Is Novavax, the latecomer COVID vaccine, worth the wait?

Medical Marketing and Media

Flag link:

Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine

Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine

Reuters

Flag link:

Valneva single-dose chikungunya vaccine poised to ‘revolutionize’ global health

Valneva single-dose chikungunya vaccine poised to ‘revolutionize’ global health

Biopharma Reporter

chikungunya virus

Flag link:

IO Biotech concludes subject enrollment in melanoma vaccine trial

IO Biotech concludes subject enrollment in melanoma vaccine trial

Clinical Trials Arena

Flag link:

FDA approves Valneva's chikungunya vaccine

FDA approves Valneva's chikungunya vaccine

Reuters

chikungunya virus

Flag link:

Novavax posts higher-than-expected revenue, says prepared to further cut costs

Novavax posts higher-than-expected revenue, says prepared to further cut costs

Reuters

Flag link:

Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.

Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.

Motley Fool

Moderna Therapeutics

Flag link:

RSV is on the rise but preventative drugs are in short supply

RSV is on the rise but preventative drugs are in short supply

MIT Technology Review

Flag link:

Moderna takes hefty $1.3B COVID write-off, scales back manufacturing as sales shrink

Moderna takes hefty $1.3B COVID write-off, scales back manufacturing as sales shrink

Fierce Pharma

Moderna Therapeutics

Flag link:

GSK outpaces Pfizer in RSV vaccine market

GSK outpaces Pfizer in RSV vaccine market

BioPharma Dive

Flag link:

Pfizer RSV vaccine gets off to fast start on market

Pfizer RSV vaccine gets off to fast start on market

BioPharma Dive

Flag link:

A continuing decline in sales of COVID-19 products clips revenue at Pfizer

A continuing decline in sales of COVID-19 products clips revenue at Pfizer

Yahoo Finance

Flag link:

Pfizer's mRNA flu vaccine hits primary goals in phase 3 trial, but secondary miss raises questions

Pfizer's mRNA flu vaccine hits primary goals in phase 3 trial, but secondary miss raises questions

Fierce Biotech

clinical trials

Flag link:

Moderna joins CEPI's 100 Days Mission to advance pandemic preparedness

Moderna joins CEPI's 100 Days Mission to advance pandemic preparedness

Fierce Biotech

Moderna Therapeutics

Flag link:

Pfizer, BioNTech prep flu-COVID mRNA combo shot for phase 3, reprising Moderna race after seeing early data

Pfizer, BioNTech prep flu-COVID mRNA combo shot for phase 3, reprising Moderna race after seeing early data

Fierce Biotech

Moderna Therapeutics

flu-COVID combo vaccines

Flag link:

Araclon vaccine appears to slow Alzheimer's in exploratory phase 2 analysis, spurring review of next steps

Araclon vaccine appears to slow Alzheimer's in exploratory phase 2 analysis, spurring review of next steps

Fierce Biotech

Alzheimer's disease

clinical trials

Flag link:

Pages